Evaluation of Improved Onboard Patient Imaging

Launched by VARIAN, A SIEMENS HEALTHINEERS COMPANY · Dec 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technology called "HyperSight" to improve how radiation therapy is delivered to patients with certain types of cancer, including head and neck, breast, lung, upper gastrointestinal, and pelvic cancers. The goal is to make sure that the radiation targets the cancer more accurately while protecting healthy tissues around it. Traditional imaging methods can sometimes lead to issues like unclear pictures or missing parts of the area being treated, which can affect treatment quality. By testing this new technology, researchers hope to enhance the accuracy of radiation therapy.

To participate in this trial, patients must be at least 18 years old and have a confirmed diagnosis of cancer that requires radiation treatment. They should be able to provide consent and have a performance status that indicates they can cope with the treatment. However, people who are pregnant, have certain medical devices, or specific genetic sensitivities to radiation cannot join. Participants will receive their radiation therapy at the University of Maryland Medical Center and will be closely monitored throughout the trial. This study aims to ensure a safer and more effective treatment process for patients undergoing radiation therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient is willing and able to provide written consent.
• • 2. Patient is at least 18 years of age at the time of consent.
• • 3. Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis.
• • 4. Patient has ECOG performance status 0-2.
• • 5. Patient will be receiving radiation therapy at University of Maryland Medical Center, Department of Radiation Oncology.
• Exclusion Criteria:
• • 1. Patient is pregnant or attempting pregnancy.
• • 2. Patient has implanted cardiac devices or nerve stimulation devices.
• • 3. Patient has known genetic pre-disposition for sensitivity to radiation (e.g., Li Fraumeni).
• • 4. Patient receives palliative radiation for 5 or fewer fractions.
• • 5. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.